MRNA Stock: Buy or Sell? Price Target & Forecast

Analyses / MRNA

MRNA Moderna Inc As of Jul 3, 2026

$79.76

Biotech recovery play: +10% today on vaccine cycle; margin collapse & revenue cliff warrant caution.

Setup: recovery / momentum Confidence: medium Horizon: 3-6 months Risk: high Category: Biotechnology

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals MRNA's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Moderna trades well below 52-week high ($81.40 today vs $81.40 weekly peak); strong balance sheet (current ratio 3.29, $31.6B market cap); beta 0.85 offers downside cushion. Insider buys outpace sells (84 vs 121 net over period). Vaccine cycles are lumpy; rebound in demand or pipeline progress could reignite valuations.

▼ Bear Case

Revenue collapsed -53% YoY; operating margin at -158%, net margin -146%. P/S of 16.1x extremely elevated for negative earnings. Book value $21.95/share vs price $79.76 suggests speculative premium. EV/EBITDA negative (company unprofitable). 52-week range $22.28–$81.40 shows wild swings; current price near highs without margin recovery proof.

Valuation

overvalued on fundamentals; momentum-driven — score 35/100

P/S 16.1x unjustifiable for -$145% net margin company. Book value $21.95 vs price $79.76 = 3.6x premium with no earnings to justify it. P/FCF 6.85x only metric in fair range, but company not consistently FCF-positive. Recovery play pricing in margin inflection without proof.

Technical Levels

Support · $72.50 (Previous close; short-term floor) · $68.00 (Stop-loss; 20-day avg ~71) · $60.00 (Psychological round number; 2024 support zone)

Resistance · $81.40 (52-week high (today's high); resistance) · $85.00 (Target; clear breakout zone) · $90.00 (Psychological; 2021–2022 range)

Financial Health

Score 72/100. Strong liquidity (current ratio 3.29, quick ratio 3.08) provides runway for R&D & operations. However, operating & net losses are severe, indicating cash burn. Runway depends on pipeline value creation & potential revenue stabilization. No dividend. Balance sheet quality alone insufficient given profitability crisis.

Catalysts

Q4 2024 earnings (likely Feb 2025)	~60 days	high; guidance on 2025 revenue & margin trajectory critical. Market reprices on EPS path confirmation or miss.
RSV vaccine ramp (if approved/launched)	6–12 months	high; new revenue stream could offset COVID decline & improve utilization.
Flu vaccine pipeline updates	ongoing	medium; incremental; less impactful than RSV but additive to diversification.
Cancer vaccine development milestones	12–24 months	medium; early-stage; long time horizon; upside optionality if successful.

Risk Flags

Operating & net margins deeply negative; no EPS—profitability recovery path unclear.

Revenue -53% YoY indicates demand cliff or product cycle downturn; lumpiness inherent to vaccine biz.

P/S 16.1x is outlier-high for unprofitable biotech; re-rating risk if pipeline misses.

Insider sells exceeded buys (121 vs 84); mixed signal despite recent price lift.

One-day +10% on thin news suggests short-squeeze or sentiment flip; watch conviction hold.

See MRNA's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock MRNA free →

More Analyses

NVDA

AAPL

TSLA

MSFT

AMZN

GOOGL

MRNA FAQ

Is MRNA a buy right now?

Moderna Inc's current read is a recovery / momentum setup with medium confidence over a 3-6 months horizon. Valuation: overvalued on fundamentals; momentum-driven. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is MRNA overvalued?

overvalued on fundamentals; momentum-driven (valuation score 35/100). P/S 16.1x unjustifiable for -$145% net margin company. Book value $21.95 vs price $79.76 = 3.6x premium with no earnings to justify it. P/FCF 6.85x only metric in fair range, but company not consistently FCF-positive. Recovery play pricing in margin inflection without proof.

What are the risks of buying MRNA?